GB1275
Clinical Trials Overview
1 trials found
About GB1275
Gb1275 is an investigational medication currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being evaluated to see if it can help slow or stop the growth of cancer cells. In the context of colorectal cancer, it has been studied in combination with other treatments like gemcitabine, nab-paclitaxel, and pembrolizumab. Gb1275 is not yet approved for use in colorectal cancer or any other cancer type. The trials are in early phases (Phase 1), meaning they are primarily focused on determining the safety and appropriate dosage of the drug, as well as looking for early signs of effectiveness.
Category
Other Medications
Mechanism
The specific way Gb1275 works (its mechanism of action) is still being investigated in clinical trials. It is designed to target processes involved in cancer cell growth and survival. Researchers are studying how it interacts with cancer cells and the body's immune system to understand its potential benefits.
1
Total Trials
0
Recruiting
0
Active
1
Completed
61
Total Enrollment
2
Countries
NCT04060342
Phase 1
Completed
61 patients
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with M...
United States, United Kingdom